Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments

Source: cancernetwork, November 2020

Well it’s become quite clear from a number of elegant studies from people like Boris Bastian and Hunter Shane about the progression of melanocytes picking up serial dysregulated oncogenes and overexpression of certain pathways.

One of the surprising features about melanoma is that the BRAF that we target with BRAF-directed targeted therapies actually develops very early in melanocytes.

Even moles have BRAF mutations and obviously moles are not melanoma.

READ THE ORIGINAL FULL ARTICLE